326 related articles for article (PubMed ID: 36180898)
1. Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer's disease.
Faridar A; Vasquez M; Thome AD; Yin Z; Xuan H; Wang JH; Wen S; Li X; Thonhoff JR; Zhao W; Zhao H; Beers DR; Wong STC; Masdeu JC; Appel SH
Acta Neuropathol Commun; 2022 Sep; 10(1):144. PubMed ID: 36180898
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T cells decrease C3-positive reactive astrocytes in Alzheimer-like pathology.
Stym-Popper G; Matta K; Chaigneau T; Rupra R; Demetriou A; Fouquet S; Dansokho C; Toly-Ndour C; Dorothée G
J Neuroinflammation; 2023 Mar; 20(1):64. PubMed ID: 36890536
[TBL] [Abstract][Full Text] [Related]
3. Imbalance of Microglial TLR4/TREM2 in LPS-Treated APP/PS1 Transgenic Mice: A Potential Link Between Alzheimer's Disease and Systemic Inflammation.
Zhou J; Yu W; Zhang M; Tian X; Li Y; Lü Y
Neurochem Res; 2019 May; 44(5):1138-1151. PubMed ID: 30756214
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of TREM2 expression exacerbates neuroinflammatory responses through TLR4-mediated MAPK signaling pathway in a transgenic mouse model of Alzheimer's disease.
Ruganzu JB; Peng X; He Y; Wu X; Zheng Q; Ding B; Lin C; Guo H; Yang Z; Zhang X; Yang W
Mol Immunol; 2022 Feb; 142():22-36. PubMed ID: 34959070
[TBL] [Abstract][Full Text] [Related]
5. The neuroprotective N-terminal amyloid-β core hexapeptide reverses reactive gliosis and gliotoxicity in Alzheimer's disease pathology models.
Lantz MJ; Roberts AM; Delgado DD; Nichols RA
J Neuroinflammation; 2023 May; 20(1):129. PubMed ID: 37245024
[TBL] [Abstract][Full Text] [Related]
6. Curcumin restores innate immune Alzheimer's disease risk gene expression to ameliorate Alzheimer pathogenesis.
Teter B; Morihara T; Lim GP; Chu T; Jones MR; Zuo X; Paul RM; Frautschy SA; Cole GM
Neurobiol Dis; 2019 Jul; 127():432-448. PubMed ID: 30951849
[TBL] [Abstract][Full Text] [Related]
7. Triggering receptor expressed on myeloid cells 2 activation downregulates toll-like receptor 4 expression and ameliorates cognitive impairment in the Aβ
Qin Z; Gu M; Zhou J; Zhang W; Zhao N; Lü Y; Yu W
Synapse; 2020 Oct; 74(10):e22161. PubMed ID: 32412103
[TBL] [Abstract][Full Text] [Related]
8. TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease.
Griciuc A; Patel S; Federico AN; Choi SH; Innes BJ; Oram MK; Cereghetti G; McGinty D; Anselmo A; Sadreyev RI; Hickman SE; El Khoury J; Colonna M; Tanzi RE
Neuron; 2019 Sep; 103(5):820-835.e7. PubMed ID: 31301936
[TBL] [Abstract][Full Text] [Related]
9. Adoptive therapy with amyloid-β specific regulatory T cells alleviates Alzheimer's disease.
Yang H; Park SY; Baek H; Lee C; Chung G; Liu X; Lee JH; Kim B; Kwon M; Choi H; Kim HJ; Kim JY; Kim Y; Lee YS; Lee G; Kim SK; Kim JS; Chang YT; Jung WS; Kim KH; Bae H
Theranostics; 2022; 12(18):7668-7680. PubMed ID: 36451854
[No Abstract] [Full Text] [Related]
10. Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist.
Ardestani PM; Evans AK; Yi B; Nguyen T; Coutellier L; Shamloo M
Neuropharmacology; 2017 Apr; 116():371-386. PubMed ID: 28089846
[TBL] [Abstract][Full Text] [Related]
11. The S1P receptor 1 antagonist Ponesimod reduces TLR4-induced neuroinflammation and increases Aβ clearance in 5XFAD mice.
Zhu Z; Zhang L; Elsherbini A; Crivelli SM; Tripathi P; Harper C; Quadri Z; Spassieva SD; Bieberich E
EBioMedicine; 2023 Aug; 94():104713. PubMed ID: 37480622
[TBL] [Abstract][Full Text] [Related]
12. Amyloid-β specific regulatory T cells attenuate Alzheimer's disease pathobiology in APP/PS1 mice.
Yeapuri P; Machhi J; Lu Y; Abdelmoaty MM; Kadry R; Patel M; Bhattarai S; Lu E; Namminga KL; Olson KE; Foster EG; Mosley RL; Gendelman HE
Mol Neurodegener; 2023 Dec; 18(1):97. PubMed ID: 38111016
[TBL] [Abstract][Full Text] [Related]
13. LPS priming before plaque deposition impedes microglial activation and restrains Aβ pathology in the 5xFAD mouse model of Alzheimer's disease.
Yang Y; García-Cruzado M; Zeng H; Camprubí-Ferrer L; Bahatyrevich-Kharitonik B; Bachiller S; Deierborg T
Brain Behav Immun; 2023 Oct; 113():228-247. PubMed ID: 37437821
[TBL] [Abstract][Full Text] [Related]
14. The effect of amyloid on microglia-neuron interactions before plaque onset occurs independently of TREM2 in a mouse model of Alzheimer's disease.
von Saucken VE; Jay TR; Landreth GE
Neurobiol Dis; 2020 Nov; 145():105072. PubMed ID: 32890775
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological ablation of astrocytes reduces Aβ degradation and synaptic connectivity in an ex vivo model of Alzheimer's disease.
Davis N; Mota BC; Stead L; Palmer EOC; Lombardero L; Rodríguez-Puertas R; de Paola V; Barnes SJ; Sastre M
J Neuroinflammation; 2021 Mar; 18(1):73. PubMed ID: 33731156
[TBL] [Abstract][Full Text] [Related]
16. Low-Dose Ionizing Radiation Modulates Microglia Phenotypes in the Models of Alzheimer's Disease.
Kim S; Chung H; Ngoc Mai H; Nam Y; Shin SJ; Park YH; Chung MJ; Lee JK; Rhee HY; Jahng GH; Kim Y; Lim YJ; Kong M; Moon M; Chung WK
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630597
[TBL] [Abstract][Full Text] [Related]
17. Integrated biology approach reveals molecular and pathological interactions among Alzheimer's Aβ42, Tau, TREM2, and TYROBP in Drosophila models.
Sekiya M; Wang M; Fujisaki N; Sakakibara Y; Quan X; Ehrlich ME; De Jager PL; Bennett DA; Schadt EE; Gandy S; Ando K; Zhang B; Iijima KM
Genome Med; 2018 Mar; 10(1):26. PubMed ID: 29598827
[TBL] [Abstract][Full Text] [Related]
18. The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function.
Marsh SE; Abud EM; Lakatos A; Karimzadeh A; Yeung ST; Davtyan H; Fote GM; Lau L; Weinger JG; Lane TE; Inlay MA; Poon WW; Blurton-Jones M
Proc Natl Acad Sci U S A; 2016 Mar; 113(9):E1316-25. PubMed ID: 26884167
[TBL] [Abstract][Full Text] [Related]
19. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.
Zhou Y; Song WM; Andhey PS; Swain A; Levy T; Miller KR; Poliani PL; Cominelli M; Grover S; Gilfillan S; Cella M; Ulland TK; Zaitsev K; Miyashita A; Ikeuchi T; Sainouchi M; Kakita A; Bennett DA; Schneider JA; Nichols MR; Beausoleil SA; Ulrich JD; Holtzman DM; Artyomov MN; Colonna M
Nat Med; 2020 Jan; 26(1):131-142. PubMed ID: 31932797
[TBL] [Abstract][Full Text] [Related]
20. Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics.
Griñán-Ferré C; Jarné-Ferrer J; Bellver-Sanchís A; Codony S; Puigoriol-Illamola D; Sanfeliu C; Oh Y; Lee S; Vázquez S; Pallàs M
CNS Neurosci Ther; 2024 Apr; 30(4):e14511. PubMed ID: 37905690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
